Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to raise $75 million by selling 4.4 million shares at $16 to $18...read more
US IPOs continued to make a strong showing this week, with 11 deals raising an aggregate of $1.6 billion in proceeds. It was the busiest week since the week of November 5, 2007, which saw 13 pricings. Performance was mixed, with an average total return of 7%;...read more
Conatus Pharmaceuticals, a biotech in Phase 2 trials developing treatments for chronic liver disease, raised $66 million by offering 6 million shares (20% more than the 5 million originally planned) at $11, the midpoint of the $10-$12 range. Conatus...read more
Liver disease biotech Vital Therapies revives IPO filing, removes original terms
Vital Therapies, a clinical-stage biotech developing treatments for acute liver failure, revived its IPO by filing an amended S-1 with the SEC on Friday. The company had previously launched a deal to raise $75 million by selling 4.4 million shares at $16 to $18...read more
US IPO Recap: 11 deals price in busiest week since November 2007, eight companies set terms
US IPOs continued to make a strong showing this week, with 11 deals raising an aggregate of $1.6 billion in proceeds. It was the busiest week since the week of November 5, 2007, which saw 13 pricings. Performance was mixed, with an average total return of 7%;...read more
Conatus Pharmaceuticals prices upsized IPO at $11 midpoint
Conatus Pharmaceuticals, a biotech in Phase 2 trials developing treatments for chronic liver disease, raised $66 million by offering 6 million shares (20% more than the 5 million originally planned) at $11, the midpoint of the $10-$12 range. Conatus...read more
12 US IPOs planned for the week of Jul 22
The following IPOs are expected to price this week: Agios Pharmaceuticals (AGIO), a biotech developing metabolic treatments for cancer and rare genetic diseases, plans...read more